Covid19MEDyMAPNCT04581096
Mapping COVID-19 Spread in a Tertiary Hospital
An observational study of Covid19 and Spatial Visualization, run by Hospital General Universitario de Valencia at 2 sites in Spain.
Trial summary
One of the major problems in suppressing the spreading of an epidemic resides in understanding and monitoring its propagation patterns, and in evaluating how these are modified by enforced policies. The standard solution requires detailed information at the microscopic scales, e.g. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Covid19, Spatial Visualization, Neural Network
- How many people
- 2,646 participants
- Where
- 2 sitesSpain
- Study dates
- 2 Oct 2020to 15 Jun 2021
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a positive test (PCR or serology) for SARS-CoV-2 in an outpatient regime system
Who may be able to join
- positive test (PCR or serology) for SARS-CoV-2
- outpatient follow-up
Who cannot join
- hospitalisation in ward or ICU
Trial locations and contacts
2 sites in 1 country.
About this study
Official title: Evaluation of the Response of COVID-19 Spread With a Spatiotemporal Analysis in a Tertiary Hospital
One of the major problems in suppressing the spreading of an epidemic resides in understanding and monitoring its propagation patterns, and in evaluating how these are modified by enforced policies. The standard solution requires detailed information at the microscopic scales, e.g. how infected people have moved and whom they came in contact with, which is hardly ever available. The researchers propose a novel approach to the study of the propagation of COVID-19, in which a proxy of this information is derived at macroscopic scales. This will be based on two ingredients: the spatiotemporal study in shiny with mathematical models with aggregated or non aggregated data and the reconstruction of functional networks of spreading patterns, and the development of a supporting software.
- Conditions
- Covid19, Spatial Visualization, Neural Network, Respiratory Disease, Pandemic, Disease Spread
- Being tested
- no intervention
- Medical subject headings
- COVID-19, Spatial Navigation, Respiration Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no interventionOther
just descriptive analysis of clinical data
What is being measured
The primary outcome is the main question the study is designed to answer.
spatiotemporal spread
spatiotemporal spread of COVID-19 patient in our hospital
Measured: February 1, 2020 to September 30, 2020
Secondary outcomes (1)
classification score
risk classification score of each patients with clinical and analytical variables
Measured: February 1, 2020 to September 30, 2020
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2020
- Study start2 Oct 2020
- Primary completion15 Feb 2021
- Study completion15 Jun 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,646 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Hospital General Universitario de Valencia
- Sponsor type
- University, hospital or other
- Collaborators
- University of Valencia
- Responsible party
- Principal investigator, Carolina Soledad Romero Garcia, MD, PhD, Hospital General Universitario de Valencia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04581096
- Sponsor's protocol ID
- COVID19-MAPA
- Acronym
- MEDyMAP
- Status last verified
- Nov 2021
- First submitted
- 7 Oct 2020
- Last updated
- 10 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: there is not ipd sharing planned
Publications
Romero Garcia C, Iftimi A, Briz-Redon A, Zanin M, Otero M, Ballester M, de Andres J, Landoni G, de Las Marinas D, Catala Bauset JC, Mandingorra J, Conca J, Correcher J, Ferrer C, Lozano M. Trends in Incidence and Transmission Patterns of COVID-19 in Valencia, Spain. JAMA Netw Open. 2021 Jun 1;4(6):e2113818. doi: 10.1001/jamanetworkopen.2021.13818.
PubMed 34143191Briz-Redon A, Iftimi A, Correcher JF, De Andres J, Lozano M, Romero-Garcia C. A comparison of multiple neighborhood matrix specifications for spatio-temporal model fitting: a case study on COVID-19 data. Stoch Environ Res Risk Assess. 2022;36(1):271-282. doi: 10.1007/s00477-021-02077-y. Epub 2021 Aug 18.
PubMed 34421343
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Response of COVID-19 Spread With a Spatiotemporal Analysis in a Tertiary Hospital
- ClinicalTrials.gov ID
- NCT04581096
- Acronym / sponsor ID
- MEDyMAP / COVID19-MAPA
- Conditions
- Covid19, Spatial Visualization, Neural Network, Respiratory Disease, Pandemic, Disease Spread
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,646 participants (actual)
- Lead sponsor
- Hospital General Universitario de ValenciaUniversity, hospital or other
- Collaborators
- University of Valencia
- Study start
- 2 Oct 2020 (actual)
- Primary completion
- 15 Feb 2021 (actual)
- Study completion
- 15 Jun 2021 (actual)
- First posted
- 9 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
One of the major problems in suppressing the spreading of an epidemic resides in understanding and monitoring its propagation patterns, and in evaluating how these are modified by enforced policies. The standard solution requires detailed information at the microscopic scales, e.g. how infected people have moved and whom they came in contact with, which is hardly ever available. The researchers propose a novel approach to the study of the propagation of COVID-19, in which a proxy of this information is derived at macroscopic scales. This will be based on two ingredients: the spatiotemporal study in shiny with mathematical models with aggregated or non aggregated data and the reconstruction of functional networks of spreading patterns, and the development of a supporting software.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Months
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a positive test (PCR or serology) for SARS-CoV-2 in an outpatient regime system
Key inclusion criteria (2 listed)
- positive test (PCR or serology) for SARS-CoV-2
- outpatient follow-up
Key exclusion criteria (1 listed)
- hospitalisation in ward or ICU
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no interventionjust descriptive analysis of clinical data | Other | – |
Primary outcome
spatiotemporal spread
Time frame: February 1, 2020 to September 30, 2020
spatiotemporal spread of COVID-19 patient in our hospital
1 secondary outcome
classification score
Time frame: February 1, 2020 to September 30, 2020
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2021.
- Background: PubMed 34143191Romero Garcia C, Iftimi A, Briz-Redon A, Zanin M, Otero M, Ballester M, de Andres J, Landoni G, de Las Marinas D, Catala Bauset JC, Mandingorra J, Conca J, Correcher J, Ferrer C, Lozano M. Trends in Incidence and Transmission Patterns of COVID-19 in Valencia, Spain. JAMA Netw Open. 2021 Jun 1;4(6):e2113818. doi: 10.1001/jamanetworkopen.2021.13818.
- Background: PubMed 34421343Briz-Redon A, Iftimi A, Correcher JF, De Andres J, Lozano M, Romero-Garcia C. A comparison of multiple neighborhood matrix specifications for spatio-temporal model fitting: a case study on COVID-19 data. Stoch Environ Res Risk Assess. 2022;36(1):271-282. doi: 10.1007/s00477-021-02077-y. Epub 2021 Aug 18.
- Individual participant dataSharing planned: No. there is not ipd sharing planned
Related trials for Covid19
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement
COVID-19
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and Spatial Visualization, run by Hospital General Universitario de Valencia at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
spatiotemporal spread (time frame: February 1, 2020 to September 30, 2020). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04581096, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2021.